Caffeine attenuates metabolic syndrome in diet-induced obese rats

Nutrition. 2012 Oct;28(10):1055-62. doi: 10.1016/j.nut.2012.02.013. Epub 2012 Jun 19.

Abstract

Objective: Caffeine is a constituent of many non-alcoholic beverages. Pharmacological actions of caffeine include the antagonism of adenosine receptors and the inhibition of phosphodiesterase activity. The A₁ adenosine receptors present on adipocytes are involved in the control of fatty acid uptake and lipolysis. In this study, the effects of caffeine were characterized in a diet-induced metabolic syndrome in rats.

Methods: Rats were given a high-carbohydrate, high-fat diet (mainly containing fructose and beef tallow) for 16 wk. The control rats were given a corn starch diet. Treatment groups were given caffeine 0.5 g/kg of food for the last 8 wk of the 16-wk protocol. The structure and function of the heart and the liver were investigated in addition to the metabolic parameters including the plasma lipid components.

Results: The high-carbohydrate, high-fat diet induced symptoms of metabolic syndrome, including obesity, dyslipidemia, impaired glucose tolerance, decreased insulin sensitivity, and increased systolic blood pressure, associated with the development of cardiovascular remodeling and non-alcoholic steatohepatitis. The treatment with caffeine in the rats fed the high-carbohydrate, high-fat diet decreased body fat and systolic blood pressure, improved glucose tolerance and insulin sensitivity, and attenuated cardiovascular and hepatic abnormalities, although the plasma lipid concentrations were further increased.

Conclusion: Decreased total body fat, concurrent with increased plasma lipid concentrations, reflects the lipolytic effects of caffeine in adipocytes, likely owing to the caffeine antagonism of A₁ adenosine receptors on adipocytes.

MeSH terms

  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Animals
  • Blood Pressure / drug effects
  • Caffeine / pharmacology
  • Caffeine / therapeutic use*
  • Cardiovascular System / drug effects
  • Cardiovascular System / pathology
  • Diet, High-Fat / adverse effects
  • Dietary Carbohydrates / adverse effects*
  • Dietary Fats / adverse effects*
  • Fatty Liver / etiology
  • Glucose Intolerance / drug therapy
  • Insulin Resistance
  • Lipids / blood*
  • Liver / abnormalities
  • Liver / drug effects
  • Male
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / metabolism
  • Obesity / blood
  • Obesity / drug therapy*
  • Obesity / etiology
  • Purinergic P1 Receptor Antagonists / pharmacology
  • Purinergic P1 Receptor Antagonists / therapeutic use
  • Rats
  • Rats, Wistar

Substances

  • Dietary Carbohydrates
  • Dietary Fats
  • Lipids
  • Purinergic P1 Receptor Antagonists
  • Caffeine